by Katie Hogan | Jul 29, 2026 | Market Access
| Author: Alison Kneen, Global Market Access Practice Lead, BioVid The timeline between clinical development and commercial launch is shrinking. Not because science is moving faster, but because regulators, HTA bodies, and market access expectations are becoming...
by Katie Hogan | Feb 25, 2026 | Market Access
Author: Alison Kneen, Global Market Access Practice Lead, BioVid Recent developments surrounding U.S. Most Favored Nation (MFN) pricing discussions and the Supreme Court’s ruling limiting tariff authority have largely been covered as isolated legal and political...
by Katie Hogan | Feb 11, 2026 | Market Access
Author: Alison Kneen, Global Market Access Practice Lead This year has seen more changes in market access than in the last few decades. The market is moving fast, driven by scientific innovation. Patient expectations are continuing to rise; health budgets are feeling...
